CBPM: Cannabis-based products for medicinal use
Cannabis-based products for medicinal use (CBPMs) were legalised in the UK in November 2018, but there are strict laws surrounding their classification and prescription.
In the UK, all pharmaceutical products that contain cannabinoids are referred to as cannabis-based products for medicinal use (CBPM). These products are derived from the cannabis plant and can contain cannabis, cannabis resin, cannabinoids or any compound extracted from the plant. These products can only be prescribed by a specialist doctor who is on the General Medical Council's Specialist Register.
How is the efficacy of CBPM determined?
The efficacy of CBPMs is determined through rigorous clinical trials and studies. The two major cannabinoids produced by cannabis plants (THC and CBD) have been extensively studied for their medicinal properties.
These studies have shown promising results in reducing the symptoms of a range of health conditions such as chronic pain, multiple sclerosis, nausea caused by chemotherapy, inflammatory issues, autoimmune diseases, and a wide range of mental health conditions.
Is dried cannabis flower a CBPM?
Yes, medical cannabis flower that has been cultivated and harvested under the strict regulations of the UK's government can be considered a CBPM. This product contains both THC and CBD in varying levels, depending on the strain.
Is medical cannabis oil a CBPM?
Yes, medical cannabis oil can also be considered a CBPM. This product is made by extracting cannabinoids from the cannabis plant and diluting it with a carrier oil, most often MCT oil. It can contain both the major cannabinoids, or just one.
To find out more about CBPMs, click here
If you would like to learn more about medical cannabis in the UK, Releaf is here to help.